(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number
WO 03/007981 A1

(51) International Patent Classification[7]: A61K 38/21, 45/00, C07K 17/00

(21) International Application Number: PCT/US02/21813

(22) International Filing Date: 9 July 2002 (09.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/307,013 20 July 2001 (20.07.2001) US

(71) Applicant *(for all designated States except US)*: **INTERMUNE PHARMACEUTICALS, INC.** [US/US]; 3280 Bayshore Boulevard, Brisbane, CA 94010-1317 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **HSU, Henry H.** [US/US]; 370 Robinwood Lane, Hillsborough, CA 94010 (US).

(74) Agent: **BORDEN, Paula A.**; Bozicevic, Field & Francis LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/007981 A1

(54) Title: METHODS OF TREATING LIVER FIBROSIS

(57) Abstract: The present invention provides methods of reducing liver fibrosis; methods of increasing liver function in an individual suffering from liver fibrosis; and methods of reducing the incidence of complications associated with cirrhosis of the liver. The methods generally involve administering a therapeutically effective amount of IFN-γ.